Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (GB:0A8E)
LSE:0A8E
Xeris Pharmaceuticals (0A8E) Share Price & Analysis
0 Followers
0A8E Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.49 - $3.25
Previous Close$1.79
Volume510.00
Average Volume (3M)9.47K
Market Cap
$250.01M
Enterprise Value$411.98M
Total Cash (Recent Filing)$65.97M
Total Debt (Recent Filing)$227.94M
Price to Earnings (P/E)N/A
Beta1.31
Next Earnings
May 08, 2024EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume703
30 Day Avg. Volume9,472
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.59
Enterprise Value/Gross Profit13.53
Enterprise Value/Ebitda-32.52
Forecast
1Y Price Target
$5.33Price Target Upside198.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Xeris Pharmaceuticals News
Options Prices
Currently, No data available
---
Ownership Overview
13.83% Insiders
8.27% Mutual Funds
9.37% Other Institutional Investors
68.53% Public Companies and
Individual Investors
0A8E FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest share price was $1.49 and its highest was $3.25 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Currently, no data Available
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is May 08, 2024 which is in 19 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Mar 06, 2024. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.085 by -$0.015.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is -$0.11.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 140,453,460 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.085. Following the earnings report the stock price went down -17.781%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Among the largest hedge funds holding Xeris Pharmaceuticals’s share is Fairfax Financial Holdings Ltd. It holds Xeris Pharmaceuticals’s shares valued at 356K.
---
Xeris Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.33 (198.60% Upside)
$5.33 (198.60% Upside)
Blogger Sentiment
Bullish
GB:0A8E Sentiment 80%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $438.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.89%
12-Months-Change
Fundamentals
Return on Equity
-324.20%
Trailing 12-Months
Asset Growth
-1.11%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.
---
0A8E Earnings Call
Q4 2024
0:00 / 0:00
---
0A8E Stock 12 Months Forecast
Average Price Target
$5.33
▲(198.60% Upside)
Technical Analysis
Xeris Pharmaceuticals
―
Seres Therapeutics
―
Ovid Therapeutics
―
Sangamo Biosciences
―
Rockwell Med
―
Best Analysts Covering 0A8E
1 Year
1 Year Success Rate
6/14 ratings generated profit
1 Year Average Return
-2.13%
reiterated a buy rating last month
Copying Oren Livnat's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -2.13% per trade.
---